Alvotech Switches CEO And Takes COO From Teva
Founder Wessman Will Replace Levick As CEO, While Fridriksdottir Joins Firm From January
Major leadership changes are being made at the top of Alvotech, with founder Robert Wessman stepping in to replace Mark Levick as CEO at the same time as Teva’s former head of global R&D, Hafrun Fridriksdottir, becomes COO of the biosimilars developer.
